Skip to content
10-Q

Quarterly Report

Gossamer Bio, Inc. GOSS

0001728117-26-000032

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 234.7M sh
Shares Diluted Q1 2026 · Mar 31, 2026 234.14M sh
Shares Diluted Q1 2026 · Mar 31, 2025 226.82M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $26K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$38.72M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$39.72M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $41.03M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $37.73M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$161.48M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$122.76M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$6.25M
Stockholders Equity Q1 2026 · Dec 31, 2024 $29.49M
Current Liabilities Q1 2026 · Mar 31, 2026 $56.51M
Current Liabilities Q1 2026 · Dec 31, 2025 $63.44M
Total Liabilities Q1 2026 · Mar 31, 2026 $290.38M
Total Liabilities Q1 2026 · Dec 31, 2025 $295.01M
Current Assets Q1 2026 · Mar 31, 2026 $124.54M
Current Assets Q1 2026 · Dec 31, 2025 $167.64M
Total Assets Q1 2026 · Mar 31, 2026 $128.9M
Total Assets Q1 2026 · Dec 31, 2025 $172.25M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.20
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.16
Eps Basic Q1 2026 · Mar 31, 2026 −$0.20
Eps Basic Q1 2026 · Mar 31, 2025 −$0.16
Sga Expense Q1 2026 · Mar 31, 2026 $18.75M
Sga Expense Q1 2026 · Mar 31, 2025 $8.66M
Net Income Q1 2026 · Mar 31, 2026 −$46.66M
Net Income Q1 2026 · Mar 31, 2025 −$36.64M
Operating Income Q1 2026 · Mar 31, 2026 −$44.87M
Operating Income Q1 2026 · Mar 31, 2025 −$36.81M
Revenue Q1 2026 · Mar 31, 2026 $16.96M
Revenue Q1 2026 · Mar 31, 2025 $9.89M